James Abell
InvestorSenior Adviser at Abingworth
About
James Abell served as Abingworth's CFO for over 20 years, overseeing finance, compliance, administration and investment matters with a focus on start-up companies, before retiring in 2019. He was previously CFO of biotech start-up Prolifix, trained as a Chartered Accountant with KPMG, and holds a degree in Biology with Chemistry from the University of Southampton. He now works as a Senior Adviser on clinical co-development deals.
Invests in
Biotech
Investments
Board seats
AvillionChroma TherapeuticsClinical DesignsSFJ PharmaceuticalsSyntaxin
Per the firm's website.
Colleagues at Abingworth
Alex Asquith
Counsel at Abingworth
Andrew Sinclair
Managing Director, Head of Publics & Late Stage at Abingworth
Ankur Shah
Vice President, CCD at Abingworth
Anna Slezak
Senior Associate at Abingworth
Bali Muralidhar
Global Head of Life Sciences & CIO at Abingworth
Carlos Paya
Venture Partner at Abingworth
Dayle Hogg
Operating Executive at Abingworth
Diya Malhotra
Principal at Abingworth